Canterbury DHB

Context

Intrathecal Therapy and SCT

In This Section

IT Methotrexate and SCT

IT Methotrexate and SCT

Each patient will be individually assessed to determine whether IT methotrexate should be given as part of the conditioning regimen. The usual indications are ALL, AML (especially M5), CML in accelerated phase (especially with prior CNS disease). However ALL schedules that incorporate high dose MTX prior to SCT do not require IT MTX at the time of conditioning.

Note: If methotrexate has been given in the 4 weeks prior to Day 0, folinic acid 15 mg IV Q12H should be given for 4 doses during the 48 hours prior to bone marrow infusion.

About this Canterbury DHB document (9197):

Document Owner:

Andrew Butler (see Who's Who)

Issue Date:

December 2016

Next Review:

December 2018

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 9197